摘要
目的:研究黄芪多糖下调MG63/ADR耐药骨肉瘤细胞的耐药机制。方法:检测并计算黄芪多糖对MG63骨肉瘤细胞株IC50的影响,将骨肉瘤耐阿霉素细胞株MG63/ADR分为CON组(未行黄芪多糖及阿霉素处理)、APS组(仅黄芪多糖处理)、ADR组(仅阿霉素处理)、A+A组(黄芪多糖联合阿霉素处理),CCK-8法检测细胞吸光度,流式细胞仪检测细胞增殖及凋亡。分别采用RT-PCR和Western Blot法检测四组细胞多药耐药相关蛋白1(MRP-1)和多药耐药1(MDR1)基因mRNA和蛋白质表达。结果:黄芪多糖体外抑制MG63骨肉瘤细胞株IC50为1.6 mg/mL。APS组和CON组、A+A组骨肉瘤耐阿霉素细胞株MG63/ADR的第1~7天吸光度、G0/G1期、S期、G2/M期、增殖指数(PI)、凋亡率、MRP-1和MDR1基因mRNA和蛋白质表达差异无统计学意义(P>0.05)。骨肉瘤耐阿霉素细胞株MG63/ADR的第1~7天吸光度、S期、G2/M期、PI、MRP-1和MDR1基因mRNA和蛋白质表达低于APS组,G0/G1期和凋亡率均高于APS组,差异均有统计学意义(P<0.05)。结论:黄芪多糖可抑制骨肉瘤细胞增殖并促进凋亡,通过抑制MRP-1和MDR1基因表达下调MG63/ADR耐药骨肉瘤细胞对阿霉素的耐药性。
Objective:To study the mechanism of astragalus polysaccharide down-regulating the drug resistance of MG63/ADR-resistant osteosarcoma cells.Methods:CCK-8 method was used to detect the astragalus polysaccharide’s IC50 on MG63/ADR-resistant osteosarcoma cells.MG63/ADR-resistant osteosarcoma cells were divided into CON group(without astragalus polysaccharide and doxorubicin treatment),APS group(astragalus polysaccharide treatment),ADR group(doxorubicin treatment),A+A group(astragalus polysaccharide and doxorubicin treatment).The differences in cell absorbance,cell cycle and apoptosis in four groups were detected and compared.RT-PCR and Western Blot were used to detect the expression of multidrug resistance-associated protein-1(MRP-1)and multidrug resistance-1(MDR-1)mRNA and protein.Results:The astragalus polysaccharide’s IC50 on MG63/ADR-resistant osteosarcoma cells 1.6 mg/mL.The day 1-day 7 absorbance,G0/G1 phase,S phase,G2/M phase,PI,apoptosis rate,MRP-1 and MDR1 expressions of MG63/ADR cell in the APS and CON,A+A groups were not statistically significant(P>0.05).The day 1-day 7 absorbance,S-phase,G2/M-phase,proliferation index(PI),MRP-1 and MDR1 gene mRNA and protein expressions in A+A group were lower than those of APS group,while G0/G1 phase and apoptosis rate were higher than the APS group,and the differences were statistically significant(P<0.05).Conclusion:Astragalus polysaccharides can inhibit the proliferation of osteosarcoma cells and promote apoptosis,and downregulate the resistance of MG63/ADR-resistant osteosarcoma cells to doxorubicin by inhibiting the expression of MRP-1 and MDR1 genes.
作者
徐进
郑璟
严力军
XU Jin;ZHENG Jing;YAN Lijun(Department of Orthopedics,Xiangyang Central Hospital,Affiliated Hospital of Hubei University of Arts and Science,Xiangyang 441021,Hubei China;Department of Ophthalmology,Xiangyang Central Hospital,Affiliated Hospital of Hubei University of Arts and Science,Xiangyang 441021,Hubei China)
出处
《中国中医骨伤科杂志》
CAS
2020年第11期6-9,共4页
Chinese Journal of Traditional Medical Traumatology & Orthopedics
关键词
骨肉瘤
黄芪多糖
耐药
机制
osteosarcoma
astragalus polysaccharide
drug resistance
mechanism
